Case Report: Bispecific CD20/CD30-targeted chimeric antigen receptor T-cell therapy for non-Hodgkin’s lymphoma
Authors:
Open Access
- 8 May 2025
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1567149
Abstract
CD19-directed CAR T-cell therapy is a breakthrough immunotherapy for B-cell malignancies. However, CD19 loss-mediated relapsed/refractory disease continues to pose a significant challenge, highlighting the urgent need for CAR T cells targeting alternative antigens. To address this issue, we developed a CD20-directed CAR T incorporated with an additional CD30-directed binder to enhance cytotoxicity toward cancer cells. Here, we report that a patient with bulky transformed follicular lymphoma was successfully treated with CD20/CD30-directed CAR-T cells. The patient received two doses of anti-CD20/CD30-CAR-T therapy administered one month apart. Complete metabolic remission was achieved 1 month after the first infusion without evidence of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS). The second dose was given as a consolidation therapy with sustained disease-free survival exceeding 12 months to date. The report underscores the promising therapeutic potential and safety profile of CD20/CD30-directed CAR T-cell therapy.Clinical Trial Registration: https://www.clinicaltrials.gov, identifier NCT06756321.Keywords
Funding Information
- Nantong Municipal Commission of Health and Family Planning
This publication has 59 references indexed in Scilit:
- Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal CancerJAMA Oncology, 2024
- C‐CAR066, a novel fully human anti‐CD20 CAR‐T therapy for relapsed or refractory large B‐cell lymphoma after failure of anti‐CD19 CAR‐T therapy: A phase I clinical studyAmerican Journal of Hematology, 2024
- Long‐term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T‐cellsAmerican Journal of Hematology, 2022
- CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphomaCytotherapy, 2022
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trialThe Lancet Oncology, 2022
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyThe Lancet, 2021
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design studyThe Lancet, 2020
- Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30− TumorsMolecular Therapy, 2019
- CD30: expression and function in health and diseaseSeminars in Immunology, 1998
- Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's diseaseCell, 1992